SAM
LENZ

Simplify Asset Management’s LENZ Therapeutics LENZ Stock Holding History

Simplify Asset Management’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-17,481
Closed -$280K – 175
2025
Q4 		$280K Buy
+17,481
New +$510K ﹤0.01% 124

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

Simplify Asset Management's LENZ Position: Q1 2026 in Review

Simplify Asset Management sold out of LENZ Therapeutics (LENZ) in Q1 2026, closing a stake of 17,481 shares — an estimated $280K sold.

Simplify Asset Management first reported a position in LENZ in Q4 2025 and held it in 1 quarter. The position peaked at $280K in Q4 2025. 145 funds tracked by Wall St. Rank hold LENZ as of Q1 2026.

  • Simplify Asset Management reported no remaining LENZ Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Simplify Asset Management sold 17,481 LENZ Therapeutics shares in Q1 2026, an estimated $280K.
  • Simplify Asset Management first reported a position in LENZ Therapeutics in Q4 2025 and held it in 1 quarter.
  • Simplify Asset Management's LENZ Therapeutics position peaked at $280K in Q4 2025.
  • 145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2026.

Based on Simplify Asset Management's 13F filing for Q1 2026, filed 27 Apr 2026.